ANNX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AN

Mkt Cap

$647.4M

Volume

4.34M

Next Earnings

November 9th

Loading chart

AN

ANNXAnnexon, Inc. Common Stock

ANNX

Pay with—

Available Balance0.00

AN

Mkt Cap

$682.5M

Volume

4.34M

Next Earnings

November 9th

Chart Financials Earnings News About Insider Filings

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)Annexon, Inc. (Nasdaq: ANNX) announced the grant of equity inducement awards to six new non-executive employees, consisting of options to purchase 1,270,000 shares of common stock at an exercise price of $3.60 per share with a ten-year term and four-year vesting schedule.GlobeNewswire Inc. · Oct 16, 2026

110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBSThe GBS|CIDP Foundation International is launching the 'GBS: 110 Years, 110 Stories' campaign to mark 110 years since the discovery of Guillain-Barré syndrome. The campaign will feature 110 patient stories in short videos to raise awareness about GBS and CIDP, rare neurological disorders. The foundation has partnered with Annexon Biosciences to promote the campaign throughout 2026, highlighting the need for advancements in patient care.GlobeNewswire Inc. · May 11, 2026

Annexon to Present at the Bank of America Securities Health Care Conference 2026Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company focused on targeted immunotherapies for neuroinflammatory diseases, announced that its President and CEO Douglas Love will present at the Bank of America Securities Health Care Conference on May 13, 2026. The company is advancing therapies targeting C1q-driven neuroinflammation, with ARCHER II pivotal Phase 3 data in geographic atrophy expected in Q4 2026.GlobeNewswire Inc. · May 6, 2026

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)Annexon, a biopharmaceutical company, granted a stock option to a new non-executive employee for 19,000 shares with a 4-year vesting schedule and an exercise price of $4.91 per share.GlobeNewswire Inc. · Dec 17, 2025

Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded WarrantsAnnexon, a biopharmaceutical company, announced a public offering of 25,096,153 shares of common stock and pre-funded warrants, expecting to raise $75 million to support its neuroinflammation research platform.GlobeNewswire Inc. · Nov 13, 2025

Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic AtrophyAnnexon completed enrollment for its Phase 3 ARCHER II trial of vonaprument, a potential treatment for dry age-related macular degeneration with geographic atrophy. The trial aims to demonstrate vision preservation and is expected to report topline data in the second half of 2026.GlobeNewswire Inc. · Jul 24, 2025

Huntington’s Disease Clinical Trial Pipeline Analysis: 20+ Key Companies Shaping the Future of Dopamine Receptor Antagonists Therapeutics | DelveInsightThe Huntington's disease treatment market is poised for significant growth, driven by rising prevalence rates, advancements in gene-targeting and disease-modifying therapies, and a robust clinical pipeline addressing critical unmet needs.GlobeNewswire Inc. · Jun 3, 2025

Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS MeetingAnnexon announced presentations at the 2025 PNS Meeting highlighting improved outcomes with its investigational therapy tanruprubart for the treatment of Guillain-Barré Syndrome (GBS), a rare autoimmune disease with no approved treatments.GlobeNewswire Inc. · May 9, 2025

Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual MeetingAnnexon, a biopharmaceutical company, is presenting data on its Phase 3 trial for ANX005, a potential treatment for Guillain-Barré Syndrome (GBS), at the AAN 2025 Annual Meeting. The company is also launching a disease education campaign to raise awareness about the impact of GBS.GlobeNewswire Inc. · Apr 3, 2025

Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceAnnexon, Inc., a biopharmaceutical company, announced that its president and CEO will present at the upcoming J.P. Morgan Healthcare Conference. The company is focused on developing novel therapies for classical complement-mediated neuroinflammatory diseases.GlobeNewswire Inc. · Jan 7, 2025

to start trading

AN

ANNXAnnexon, Inc. Common Stock

ANNX

Pay with—

Available Balance0.00

Your PositionYou don't own any ANNX yet.

Related Tickers

Earnings